Hepagene Therapeutics (Sahnghai) Co. Ltd.

Primary objective: To evaluate the pharmacokinetic (PK) characteristics and safety of HPG1860 after single and multiple oral administration in healthy adult Chinese subjects, and to compare with the previously obtained Phase I clinical data of healthy adult U.S. subjects to verify the insensitivity of racial differences in HPG1860 exposure, and to bridge the PK data and safety data of healthy U.S. subjects. Secondary objective: To evaluate the pharmacodynamic (PD) characteristics of HPG1860 after single and multiple oral administration in healthy adult Chinese subjects.